Skip to main content

Table 1 Patient Baseline Demographic and Clinical Characteristics

From: Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies

Characteristic

Patient

 

No

%

Sex

  

   Male

26

56.5

   Female

20

43.5

Age, years

  

   Median

51

 

   Range

23-68

 

ECOG performance status

  

   0

8

17.4

   1

36

78.3

   2

2

4.3

Prior Therapy

46

 

   Chemotherapy (including cytokine and TKI)

  

1

21

 

2

10

 

≥3

15

 

   Radiotherapy

13

 

   Surgery

39

 

   Other (Endocrine/Intervention)

7

 

Measurability of baseline disease

  

   Measurable

45

97.8

   Unmeasurable

1

2.1

Primary tumor site

  

   Gastrointestinal tract

34

73.9

   Bronchus/Lung

3

6.5

   Breast

3

6.5

   Other

6

13

  1. Abbreviation: ECOG, Eastern Cooperative Oncology Group